Comparison of efficacy and safety in the combination therapies of duloxetine and S-flurbiprofen plaster, and of duloxetine and conventional NSAIDs for chronic pain in patients with osteoarthritis (OASIS DUAL study)
Drug Discoveries & Therapeutics · 31.10.2022 · 16 (5) · 217-224
DOI: 10.5582/ddt.2022.01052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Discoveries & Therapeutics, erschienen am 31.10.2022. Verfasst von Kenzo Koyama. Beteiligte Einrichtung: Nagasaki Orthopaedic Koyama Clinic, Nagayo, Nishisonogi, Nagasaki, Japan. Hauptthemen laut MEDLINE: Flurbiprofen, Chronic Pain, Osteoarthritis, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nagasaki Orthopaedic Koyama Clinic, Nagayo, Nishisonogi, Nagasaki, Japan.
Zitieren
APA
Koyama, K. (2022). Comparison of efficacy and safety in the combination therapies of duloxetine and S-flurbiprofen plaster, and of duloxetine and conventional NSAIDs for chronic pain in patients with osteoarthritis (OASIS DUAL study). Drug Discoveries & Therapeutics, 16(5), 217-224. https://doi.org/10.5582/ddt.2022.01052
Vancouver
Koyama K. Comparison of efficacy and safety in the combination therapies of duloxetine and S-flurbiprofen plaster, and of duloxetine and conventional NSAIDs for chronic pain in patients with osteoarthritis (OASIS DUAL study). Drug Discoveries & Therapeutics. 2022;16(5):217-224. doi:10.5582/ddt.2022.01052
BibTeX
@article{Koyama2022,
author = {Koyama, Kenzo},
title = {Comparison of efficacy and safety in the combination therapies of duloxetine and S-flurbiprofen plaster, and of duloxetine and conventional NSAIDs for chronic pain in patients with osteoarthritis (OASIS DUAL study)},
journal = {Drug Discoveries & Therapeutics},
year = {2022},
volume = {16},
number = {5},
pages = {217--224},
doi = {10.5582/ddt.2022.01052}
}
EUVIMED